Daptomycin plus fosfomycin versus daptomycin monotherapy in treating MRSA: protocol of a multicentre, randomised, phase III trial

Introduction: Despite the availability of new antibiotics such as daptomycin, methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia continues to be associated with high clinical failure rates. Combination therapy has been proposed as an alternative to improve outcomes but there is a lack of...

ver descrição completa

Detalhes bibliográficos
Autores: Shaw, E., Miro, J. M., Puig-Asensio, M., Pigrau, C., Barcenilla, F., Murillas Angoiti, Javier, Garcia-Pardo, G., Espejo, Elena, Padilla, Belen, Garcia-Reyne, A., Pasquau, Juan, Rodriguez-Bano, Jesus, Lopez-Contreras, J., Montero, M., de la Calle, Cristina, Pintado, V., Calbo, Esther, Gasch, O., Montejo, M., Salavert Lleti, Miguel, Garcia-Pais, M. J., Carratalà, Jordi, Pujol, José Manuel, Spanish Network Res Infect Dis REI, Inst Salud Carlos III Madrid Spain, GEIH Hosp Infection Study Grp
Formato: artículo
Fecha de publicación:2015
País:España
Recursos:Conselleria de Salut i Consum del Govern de les Illes Balears
Repositorio:Docusalut
Idioma:inglés
OAI Identifier:oai:docusalut.com:20.500.13003/17189
Acesso em linha:https://hdl.handle.net/20.500.13003/17189
Access Level:acceso abierto
Palavra-chave:Adolescent
Daptomycin
Staphylococcal Infections
Treatment Outcome
Methicillin-Resistant Staphylococcus aureus
Research Design
Bacteremia
Drug Combinations
Adult
Anti-Bacterial Agents
Microbial Sensitivity Tests
Fosfomycin
Humans
Staphylococcus aureus Resistente a Meticilina
Adolescente
Adulto
Infecciones Estafilocócicas
Daptomicina
Resultado del Tratamiento
Antibacterianos
Proyectos de Investigación
Combinación de Medicamentos
Pruebas de Sensibilidad Microbiana
Humanos
Fosfomicina
Bacteriemia
Descrição
Resumo:Introduction: Despite the availability of new antibiotics such as daptomycin, methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia continues to be associated with high clinical failure rates. Combination therapy has been proposed as an alternative to improve outcomes but there is a lack of clinical studies. The study aims to demonstrate that combination of daptomycin plus fosfomycin achieves higher clinical success rates in the treatment of MRSA bacteraemia than daptomycin alone. Methods and analysis: A multicentre open-label, randomised phase III study. Adult patients hospitalised with MRSA bacteraemia will be randomly assigned (1:1) to group 1: daptomycin 10 mg/kg/24 h intravenous; or group 2: daptomycin 10 mg/kg/24 h intravenous plus fosfomycin 2 gr/6 g intravenous. The main outcome will be treatment response at week 6 after stopping therapy (test-of-cure (TOC) visit). This is a composite variable with two values: Treatment success: resolution of clinical signs and symptoms (clinical success) and negative blood cultures (microbiological success) at the TOC visit. Treatment failure: if any of the following conditions apply: (1) lack of clinical improvement at 72 h or more after starting therapy; (2) persistent bacteraemia (positive blood cultures on day 7); (3) therapy is discontinued early due to adverse effects or for some other reason based on clinical judgement; (4) relapse of MRSA bacteraemia before the TOC visit; (5) death for any reason before the TOC visit. Assuming a 60% cure rate with daptomycin and a 20% difference in cure rates between the two groups, 103 patients will be needed for each group (alpha:0.05, beta: 0.2). Statistical analysis will be based on intention to treat, as well as per protocol and safety analysis. Ethics and dissemination: The protocol was approved by the Spanish Medicines and Healthcare Products Regulatory Agency (AEMPS). The sponsor commits itself to publishing the data in first quartile peer-review journals within 12 months of the completion of the study.

Registos relacionados